Background: Cardiac allograft vasculopathy (CAV) is considered a major cause of morbidity and mortality in transplant recipients and may reflect immune-mediated endothelial injury in response to the donor heart. Elevated troponin levels in the donor serum might provide a marker for this phenomenon; therefore, we evaluated the relationship of donor troponin levels to the development of CAV.
Methods: A retrospective analysis of troponin levels was undertaken from cardiac donor patients, and transplant recipients were monitored for the development of vasculopathy by angiography (N = 171).
Results: Angiographically significant CAV developed in 6% of transplantation patients and troponin levels were inversely related to the severity of CAV.
Conclusions: Elevated donor troponin levels are not associated with the development of CAV but rather with a significantly reduced long-term risk of developing CAV, suggesting a possible protective effect of donor released protein.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.healun.2005.05.021 | DOI Listing |
Front Mol Med
January 2025
Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
Immune-checkpoint-inhibitors (ICI) target key regulators of the immune system expressed by cancer cells that mask those from recognition by the immune system. They have improved the outcome for patients with various cancer types, such as melanoma. ICI-based therapy is frequently accompanied by immune-related adverse side effects (IRAEs).
View Article and Find Full Text PDFEur J Clin Invest
January 2025
Cellular and Molecular Cardiology Research Unit, IDIS, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
Background And Aims: Meteorin-like protein (Metrnl) has been recently suggested as a new adipokine with protective cardiovascular effects. Its circulating levels in patients seem to be associated with heart failure (HF), although with contradictory results. Our aim was to ascertain whether this adipokine could estimate the prognosis of HF in de novo HF (DNHF) patients.
View Article and Find Full Text PDFBr J Hosp Med (Lond)
December 2024
Department of Emergency, Peking University People's Hospital, Beijing, China.
Secondary hemophagocytic lymphohistiocytosis (sHLH) is a rare, rapidly progressive and highly lethal disease. This retrospective cohort study aims to analyze the factors influencing the mortality risk in adult patients with sHLH, which are instrumental to improving our understanding of the high mortality risks associated with sHLH. This study included 85 patients diagnosed with sHLH who were admitted and treated in the Department of Emergency, Peking University People's Hospital between April 2015 and July 2023.
View Article and Find Full Text PDFCureus
December 2024
College of Nursing and Health Sciences, Jazan University, Jazan, SAU.
Cardiac complications following non-cardiac surgeries are a significant cause of perioperative morbidity and mortality. This meta-analysis aimed to assess the incidence and predictors of cardiac complications in patients undergoing elective and urgent non-cardiac surgeries. A comprehensive literature search was conducted in PubMed, Embase, and Cochrane Library databases for studies published between 2010 and 2024.
View Article and Find Full Text PDFFront Pharmacol
January 2025
Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Türkiye.
Aim: The current study aimed to investigate the protective effects of adenosine triphosphate (ATP), metyrosine, and melatonin on possible methylphenidate cardiotoxicity in rats using biochemical and histopathological methods.
Methods: Thirty rats were separated into five groups: healthy (HG), methylphenidate (MP), ATP + methylphenidate (ATMP), metyrosine + methylphenidate (MSMP), and melatonin + methylphenidate (MLMP). ATP (5 mg/kg) was given intraperitoneally once daily, metyrosine (50 mg/kg) orally twice daily, and melatonin (10 mg/kg) orally once daily.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!